Photo from annalsofoncology.org
May 9, 2024, 11:35
Vivek Subbiah: SERENA-1 monotherapy results in Annals of Oncology
Quoting Vivek Subbiah on X: .
“A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results – Annals of Oncology.”
Read further.
Source: Vivek Subbiah/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA).
He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 30, 2025, 04:13
Mar 30, 2025, 03:45
Mar 30, 2025, 03:26
Mar 30, 2025, 03:18
Mar 29, 2025, 23:14
Mar 29, 2025, 23:04